ClinicalTrials.gg
CompletedNCT00783289Updated Dec 27, 2019Results posted

A Phase 2a Study to Evaluate the Safety and Tolerability of Benralizumab (MEDI-563) in Adults With Asthma

A Phase 2 interventional study of Placebo and Benralizumab 25 mg in Asthma, sponsored by MedImmune LLC. Completed at 6 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2019-12-27.

Sponsored by MedImmune LLC (part of AstraZeneca) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
35
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 39 studies testing benralizumab in Asthma — 3 open to participants now, 4 under way, 2 of them phase 3. benralizumab · Asthma.

Enrollment
33rd of 39
35 · median 128
Started
2008
with 1 other
Phase 2
7 of 39
none open now
Registered
4th of 39
by date
Lead sponsor
5 of 39
MedImmune LLC

Among the 39 studies testing benralizumab in Asthma, this one is the 33rd largest by enrollment, is one of 2 that started in 2008, is one of 7 in phase 2, and was the 4th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

3 of the 39 studies testing benralizumab in Asthma are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About benralizumab

benralizumab: first FDA approval 2017 (FASENRA), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 39 studies testing benralizumab in Asthma, or all of them as a file.
02

Study summary

The primary objective of this study is to evaluate the safety and tolerability of escalating multiple subcutaneous (SC) doses of MEDI-563 in adult subjects with asthma.

Read the detailed description

This is a Phase 2a, randomized, double-blind, placebo-controlled, dose-escalation, multicenter study to evaluate the safety, tolerability, pharmacokinetics, and immunogenicity of multiple subcutaneous doses (25, 100, or 200 milligram [mg]) of benralizumab (MEDI-563) in adult subjects with asthma.

03

Conditions studied

  • Asthma

Browse trials for

Keywords

  • Asthma
  • Benralizumab
  • MEDI-563
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female subjects
  • Age 18 through 80 years at screening
  • Written and Health Insurance Portability and Accountability Act (HIPAA) authorization obtained from the subject prior to performing any protocol-related procedures, including screening evaluations
  • Previously documented diagnosis of asthma of more than or equal to (>=) 1 year duration, based on episodic symptoms of airflow obstruction; post-bronchodilator reversibility of airflow obstruction >=12 percent (%) (at screening or documented within 1 year prior to randomization); or proof of a positive response to a methacholine challenge (documented within 1 year prior to randomization) as represented by a provoking concentration of methacholine to cause a 20% fall in (FEV1); (PC20) less than (\<) 8 milligram per milliliter (mg/mL)
  • Weight of >=45 kilogram (kg) but less than or equal to (\<=) 135 kg (>=100 pounds [lb] but \<=300 lb)
  • Able to produce spirometry readings that meet American Thoracic Society (ATS)/European Respiratory Society (ERS) standards
  • Screening pre-bronchodilator FEV1 >=60%
  • Women of , unless surgically sterile (including tubal ligation) and/or at least 2 years , must use 2 effective methods of avoiding pregnancy (including oral, transdermal, or implanted , intrauterine device, female condom with spermicide, diaphragm with spermicide, cervical cap, abstinence, use of a condom with spermicide by the sexual partner, or sterile sexual partner) for 14 days prior to the first dose of the product on Study Day 0, and must agree to continue using such precautions through Study Day 161. Cessation of birth control after this point should be discussed with a responsible physician
  • Men, unless surgically sterile, must likewise use 2 effective methods of birth control (for example, condom with spermicide) and must agree to continue using such contraceptive precautions through End of Study/Study Day 161
  • Ability to complete the study period, including follow-up period until Study Day 161 as required by protocol

Exclusion criteria

Exclusion Criteria:

  • Previously received benralizumab (MEDI-563)
  • History of allergy or reaction to any component of the product formulation
  • History of allergy or reaction to any other marketed or experimental monoclonal antibody therapies, intravenous gammaglobulin (IVIG), or blood products
  • Receipt of any investigational drug therapy within 30 days prior to randomization into the study or any biologic(s) within 5 half-lives of the agent prior to randomization into the study
  • Treatment with an oral or systemic burst of within 4 weeks prior to randomization into the study
  • Use of any chronic systemic drugs, including oral corticosteroids within 4 weeks prior to randomization into the study
  • Current use of any oral or ophthalmic beta-adrenergic antagonist (for example, propranolol), must have been stopped 2 weeks prior to randomization into the study
  • Current allergy vaccination (immunotherapy)
  • History of anaphylaxis
  • Lung disease other than persistent asthma (for example, chronic bronchitis, cystic fibrosis, [COPD], tuberculosis [TB])
  • Acute illnesses or evidence of significant active infection, such as fever >=38.0 degrees Celsius [C] (>=100.5 degrees Fahrenheit [F]) at screening and up through time of the first dose of the investigational product
  • History of ingestion of untreated water in a location known to be infected with parasites, resulting in acute or chronic diarrhea; or an untreated parasitic infection within 1 month of randomization
  • Pregnancy (women of must have a negative serum pregnancy test at screening and a negative urine pregnancy test prior to administration of the investigational product)
  • Lactating woman
  • Infection with (HIV)-1, HIV-2, or hepatitis A, B, or C virus
  • History of cancer, apart from basal cell carcinoma or in situ carcinoma of the cervix treated with apparent success with curative therapy >= 1 year prior to randomization into the study
  • History of cigarette smoking >=10 pack years
  • History of alcohol abuse or drug abuse that required treatment \<1 year prior to randomization into the study
  • Elective surgery planned during the study period
  • Evidence of any systemic disease or any finding upon physical examination, laboratory abnormality, chest x-ray (CXR), or (ECG) that, in the opinion of the investigator or medical monitor, may compromise the safety of the subject in the study or confound the analysis of the study results
  • Employees of the clinical study site or any other individuals involved with the conduct of the study, or first degree family members of such individuals (that is, parents, siblings, or children)
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
35 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Placebo matched to benralizumab (MEDI-563) injection subcutaneously on Day 0, 28, and 56.

    Other: Placebo

  • Experimental
    Benralizumab 25 mg

    Benralizumab (MEDI-563) injection 25 milligram (mg) subcutaneously on Day 0, 28, and 56.

    Biological: Benralizumab 25 mg

  • Experimental
    Benralizumab 100 mg

    Benralizumab (MEDI-563) injection 100 mg subcutaneously on Day 0, 28, and 56.

    Biological: Benralizumab 100 mg

  • Experimental
    Benralizumab 200 mg

    Benralizumab (MEDI-563) injection 200 mg subcutaneously on Day 0, 28, and 56.

    Biological: Benralizumab 200 mg

Interventions

  • OtherPlacebo

    Placebo matched to benralizumab (MEDI-563) injection subcutaneously on Day 0, 28, and 56.

  • Benralizumab (MEDI-563) injection 25 milligram (mg) subcutaneously on Day 0, 28, and 56.

    Also known as: MEDI-563

  • Benralizumab (MEDI-563) injection 100 mg subcutaneously on Day 0, 28, and 56.

    Also known as: MEDI-563

  • Benralizumab (MEDI-563) injection 200 mg subcutaneously on Day 0, 28, and 56.

    Also known as: MEDI-563

06

What researchers measure

Primary outcomes

  1. Number of Participants Reporting Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)

    An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between first dose of study drug and up to Day 161 that were absent before treatment or that worsened relative to pre-treatment state.

    Time frame: Day 0 to Day 161

Secondary outcomes

  1. Time to Reach Maximum Observed Serum Concentration (Tmax) for Benralizumab

    Time frame: Day 0, 1, 7, 28, 35, 56, 84, 112, and 161

  2. Maximum Observed Serum Concentration (Cmax) for Benralizumab

    Time frame: Day 0, 1, 7, 28, 35, 56, 84, 112, and 161

  3. Area Under the Curve From Time 0 to Infinity (AUC [0-infinity]) for Benralizumab

    Area under the serum concentration-time curve from time-zero extrapolated to infinity postdose.

    Time frame: Day 0, 1, 7, 28, 35, 56, 84, 112, and 161

  4. Terminal Phase Elimination Half-Life (t1/2) for Benralizumab

    Terminal phase elimination half-life (t1/2) is the time measured for the serum concentration to decrease by one half.

    Time frame: Day 0, 1, 7, 28, 35, 56, 84, 112, and 161

  5. Number of Participants Exhibiting Anti-Drug Antibodies (ADAs) to Benralizumab at Any Visit

    Time frame: Day 0, 28, 56, 84, 112, and 161

07

Results

Posted Dec 27, 2019

Participant flow

Participant flow — Overall Study
MilestonePlaceboBenralizumab 25 mgBenralizumab 100 mgBenralizumab 200 mg
Started6766
Completed6666
Not completed0100
Withdrew: Protocol violation0100

Outcome measures

PrimaryNumber of Participants Reporting Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)

An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between first dose of study drug and up to Day 161 that were absent before treatment or that worsened relative to pre-treatment state.

Time frame:
Day 0 to Day 161
Reported as:
Number · participants
Number of Participants Reporting Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)
participantsPlaceboBenralizumab 25 mgBenralizumab 100 mgBenralizumab 200 mg
TEAEs3444
TESAEs0000
SecondaryTime to Reach Maximum Observed Serum Concentration (Tmax) for Benralizumab
Time frame:
Day 0, 1, 7, 28, 35, 56, 84, 112, and 161
Reported as:
Median · days
Time to Reach Maximum Observed Serum Concentration (Tmax) for Benralizumab
daysBenralizumab 25 mgBenralizumab 100 mgBenralizumab 200 mg
Time to Reach Maximum Observed Serum Concentration (Tmax) for Benralizumab7.00 (7.00 to 28.00)7.00 (1.00 to 7.00)7.00 (7.00 to 7.00)
SecondaryMaximum Observed Serum Concentration (Cmax) for Benralizumab
Time frame:
Day 0, 1, 7, 28, 35, 56, 84, 112, and 161
Reported as:
Mean · microgram per milliliter (mcg/mL)
Maximum Observed Serum Concentration (Cmax) for Benralizumab
microgram per milliliter (mcg/mL)Benralizumab 25 mgBenralizumab 100 mgBenralizumab 200 mg
Maximum Observed Serum Concentration (Cmax) for Benralizumab1.152 ± 0.6154.127 ± 1.77515.637 ± 8.062
SecondaryArea Under the Curve From Time 0 to Infinity (AUC [0-infinity]) for Benralizumab

Area under the serum concentration-time curve from time-zero extrapolated to infinity postdose.

Time frame:
Day 0, 1, 7, 28, 35, 56, 84, 112, and 161
Reported as:
Mean · microgram*day per milliliter
Area Under the Curve From Time 0 to Infinity (AUC [0-infinity]) for Benralizumab
microgram*day per milliliterBenralizumab 25 mgBenralizumab 100 mgBenralizumab 200 mg
Area Under the Curve From Time 0 to Infinity (AUC [0-infinity]) for Benralizumab118.335 ± 69.640405.868 ± 205.8561157.013 ± 86.444
SecondaryTerminal Phase Elimination Half-Life (t1/2) for Benralizumab

Terminal phase elimination half-life (t1/2) is the time measured for the serum concentration to decrease by one half.

Time frame:
Day 0, 1, 7, 28, 35, 56, 84, 112, and 161
Reported as:
Mean · days
Terminal Phase Elimination Half-Life (t1/2) for Benralizumab
daysBenralizumab 25 mgBenralizumab 100 mgBenralizumab 200 mg
Terminal Phase Elimination Half-Life (t1/2) for Benralizumab17.163 ± 2.36818.610 ± 3.90518.315 ± 3.484
SecondaryNumber of Participants Exhibiting Anti-Drug Antibodies (ADAs) to Benralizumab at Any Visit
Time frame:
Day 0, 28, 56, 84, 112, and 161
Reported as:
Number · participants
Number of Participants Exhibiting Anti-Drug Antibodies (ADAs) to Benralizumab at Any Visit
participantsPlaceboBenralizumab 25 mgBenralizumab 100 mgBenralizumab 200 mg
Number of Participants Exhibiting Anti-Drug Antibodies (ADAs) to Benralizumab at Any Visit0112

Adverse events

Collected over Day 0 to Day 161. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—0/6 (0%)3/6 (50%)
Benralizumab 25 mg—0/7 (0%)4/7 (57.1%)
Benralizumab 100 mg—0/6 (0%)4/6 (66.7%)
Benralizumab 200 mg—0/6 (0%)4/6 (66.7%)
Most frequent other events
Showing 10 of 26
Most frequent other events
EventPlaceboBenralizumab 25 mgBenralizumab 100 mgBenralizumab 200 mg
Oral candidiasisInfections and infestations2/60/70/60/6
Upper respiratory tract infectionInfections and infestations1/60/71/62/6
HeadacheNervous system disorders0/60/72/60/6
AsthmaRespiratory, thoracic and mediastinal disorders0/62/70/61/6
PyrexiaGeneral disorders0/60/70/61/6
Gastrointestinal viral infectionInfections and infestations0/60/70/61/6
Oral herpesInfections and infestations0/60/70/61/6
Respiratory tract infection viralInfections and infestations0/60/70/61/6
SinobronchitisInfections and infestations0/60/70/61/6
Viral infectionInfections and infestations1/60/71/60/6

Baseline characteristics

Intent-to-treat (ITT) population included all participants randomized into the study.

Age, Continuous
Age, Continuous(years)PlaceboBenralizumab 25 mgBenralizumab 100 mgBenralizumab 200 mgTotal
Mean45.7 ± 11.250.4 ± 12.345.5 ± 13.440.2 ± 12.545.6 ± 12.2
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboBenralizumab 25 mgBenralizumab 100 mgBenralizumab 200 mgTotal
Female344314
Male332311
08

Study locations

6 sites
  • Research Site
    Encinitas, California, United States
  • Research Site
    Los Angeles, California, United States
  • Research Site
    Colorado Springs, Colorado, United States
  • Research Site
    Wheaton, Maryland, United States
  • Allergy Associates Research Center
    Portland, Oregon 97213, United States
  • Research Site
    Upland, Pennsylvania, United States
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2008 to primary completion in Nov 2009, 12 months.

Results were first posted in Dec 2019, 10 years 1 month after primary completion. A results delay was requested in Jun 2012.

Of 137 industry-sponsored phase 2 interventional studies under Asthma, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 23. This study's 12 months is below that.

Counting every sponsor, half of 199 studies reached it within 20 months; a quarter within 12 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 30, 2008
First posted
Oct 31, 2008
StartActual
Nov 14, 2008
Primary completionActual
Nov 17, 2009
CompletionActual
Nov 17, 2009
Results delay requested
Jun 28, 2012
Results first posted
Dec 27, 2019
Last update
Dec 27, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 27, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00783289
Lead sponsor
MedImmune LLC
Responsible party
Sponsor
First posted
Oct 31, 2008
Start date
Nov 14, 2008
Primary completion
Nov 17, 2009
Completion
Nov 17, 2009
Results posted
Dec 27, 2019
Last update
Dec 27, 2019

Study contacts

David Gossage, M.D.
study director · MedImmune LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Benralizumab

Start the discussion